ReviewAllergy2013
EAACI position statement on asthma exacerbations and severe asthma.
Review in Allergy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Anti-IL-5 therapies for asthma.The Cochrane database of systematic reviews · 2022Pooled it
- Anti-IL5 therapies for asthma.The Cochrane database of systematic reviews · 2017Pooled it
- Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials.Respiratory research · 2023Trial
- Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma.BMC pulmonary medicine · 2019Trial
- A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.The European respiratory journal · 2017Trial
- A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.Respiratory research · 2015Trial
- Work-related asthma in adults with severe asthma from the Korean Severe Asthma Registry (KoSAR).The World Allergy Organization journal · 2024Article
- Impact of COVID-19 measures on exacerbation rates and healthcare visits in US asthma patients.Allergy and asthma proceedings · 2023Article
- Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.International journal of molecular sciences · 2023Observational
- A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases.BMC medical informatics and decision making · 2023Article
- Audit of Asthma Exacerbation Management in a Swiss General Hospital.Respiration; international review of thoracic diseases · 2023Observational
- Relationship between serum iron and blood eosinophil counts in asthmatic adults: data from NHANES 2011-2018.Frontiers in immunology · 2023Article
- Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort.Clinical and translational medicine · 2022Article
- Effect of intrabronchial administration of autologous adipose-derived mesenchymal stem cells on severe equine asthma.Stem cell research & therapy · 2022Article
- A, B, and C Rhinoviruses: New Knowledge from an Impressive Consortium. A Step Forward for Rhinovirus Vaccine Efforts or a Step Back?American journal of respiratory and critical care medicine · 2021Article
- VALIDA project: Validation of allergyAdvances in laboratory medicine · 2020Review
- Asthma attacks in children are always preceded by poor asthma control: myth or maxim?Breathe (Sheffield, England) · 2020Article
- Addressing the risk domain in the long-term management of pediatric asthma.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2020Review
- Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2020Article
- Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.Risk management and healthcare policy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Asthma exacerbations and severe asthma are linked with high morbidity, significant mortality and high treatment costs. Recurrent asthma exacerbations cause a decline in lung function and, in childhood, are linked to development of persistent asthma. This position paper, from the European Academy of Allergy and Clinical Immunology, highlights the shortcomings of current treatment guidelines for patients suffering from frequent asthma exacerbations and those with difficult-to-treat asthma and severe treatment-resistant asthma. It reviews current evidence that supports a call for increased awareness of (i) the seriousness of asthma exacerbations and (ii) the need for novel treatment strategies in specific forms of severe treatment-resistant asthma. There is strong evidence linking asthma exacerbations with viral airway infection and underlying deficiencies in innate immunity and evidence of a synergism between viral infection and allergic mechanisms in increasing risk of exacerbations. Nonadherence to prescribed medication has been identified as a common clinical problem amongst adults and children with difficult-to-control asthma. Appropriate diagnosis, assessment of adherence and other potentially modifiable factors (such as passive or active smoking, ongoing allergen exposure, psychosocial factors) have to be a priority in clinical assessment of all patients with difficult-to-control asthma. Further studies with improved designs and new diagnostic tools are needed to properly characterize (i) the pathophysiology and risk of asthma exacerbations, and (ii) the clinical and pathophysiological heterogeneity of severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.